Literature DB >> 32141321

The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy.

Duoying Wang1,2, Dong Guo3, Aijie Li1,2, Peiliang Wang2, Feifei Teng2, Jinming Yu2.   

Abstract

Aim: To investigate the predictive potential of post-treatment neutrophil-to-lymphocyte ratio (NLR) and changes in this ratio (ΔNLR) for stage III non-small-cell lung cancer (NSCLC) patients who received conventionally fractionated radiotherapy (CFRT). Patients & methods: The data of 168 NSCLC patients treated at the Shandong Cancer Hospital were analyzed retrospectively. The relationship between progression-free survival (PFS), overall survival (OS) and post-treatment NLR and ΔNLR were analyzed using both Kaplan-Meier and Cox regression methods.
Results: Kaplan-Meier survival analyses showed that post-treatment NLR and ΔNLR were associated with PFS (p < 0.001) and OS (p < 0.001) after CFRT. Multivariate analyses revealed that ΔNLR was an independent predictor of PFS (p = 0.001) and OS (p = 0.018). Post-treatment NLR can only be used as an independent predictor of PFS (p = 0.040).
Conclusion: Our results demonstrated the prognostic value of the ΔNLR in predicting PFS and OS in stage III NSCLC patients undergoing CFRT. However, post-treatment NLR has predictive value only for PFS.

Entities:  

Keywords:  changes in neutrophil-to-lymphocyte ratio; non-small-cell lung cancer; prognosis; radiotherapy; survival

Year:  2020        PMID: 32141321     DOI: 10.2217/fon-2019-0837

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  2 in total

1.  Neutrophil-to-Lymphocyte Ratio After Definitive Concurrent Chemoradiotherapy Predicts Survival in Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Hyeon Kang Koh; Younghee Park; Taeryool Koo; Hae Jin Park; Me Yeon Lee; Ah Ram Chang; Semie Hong; Hoonsik Bae
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

2.  Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer.

Authors:  Kayoko Ohnishi; Hitoshi Ishikawa; Kensuke Nakazawa; Toshihiro Shiozawa; Yutaro Mori; Masatoshi Nakamura; Toshiyuki Okumura; Ikuo Sekine; Nobuyuki Hizawa; Hideyuki Sakurai
Journal:  Thorac Cancer       Date:  2021-03-06       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.